What is the forecasted growth rate for the GM-CSF ELISA Kit market?

Analysts project a 7.4% CAGR through 2030, lifting the GM-CSF ELISA Kit market size to USD 470 million by the end of the decade.

Which factors are the key drivers of market expansion?

Surging cytokine biomarker adoption, personalized cancer immunotherapy trials, and increased government immuno-oncology budgets propel demand for standardized GM-CSF ELISA kits.

What challenges restrain faster growth?

High antibody kit costs, batch-to-batch variability, and stringent FDA/EU validation rules for companion diagnostics create entry barriers and elongate purchase cycles.

Which regions lead consumption?

North America holds 42% share, followed by Europe (28%); however, China's biotech boom positions Asia-Pacific as the fastest-growing region with >9% CAGR.

Who are the top companies competing in this space?

Thermo Fisher, R&D Systems-Bio-Techne, Abcam, Invitrogen, and Merck dominate through broad catalog portfolios, GMP-grade reagents, and global distribution contracts with CROs.

What future opportunities offer the highest upside?

Point-of-care multiplex panels, AI-guided assay optimization, and companion diagnostic partnerships for CAR-T therapies represent high-margin avenues poised to reshape the future outlook.

How is technology reshaping kit performance?

Magnetic-bead chemiluminescence, recombinant nanobody capture, and cloud-based standard-curve analytics simultaneously boost sensitivity to 0.5 pg/mL and halve assay time to <2 hours.

What is the current regulatory landscape?

FDA classifies kits as Class I IVDs; post-pandemic EU IVDR requires notified-body review, pushing vendors to implement risk management and real-world performance surveillance.

Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Intelligence Report 2026 — Updated June 2026

Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit by Type (Human, Mouse, Rat, Porcine, Others, World Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Production), by Application (Hospital, Research Institute, Others, World Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Production), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 124

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 124

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Overview

The Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) ELISA Kit market supplies immunoassay tools that quantify GM-CSF in serum, plasma, and cell-culture supernatants, underpinning inflammation, immuno-oncology, and autoimmune research. With the GM-CSF ELISA Kit market size estimated at USD 186 million in 2025 and a projected CAGR of 7.1% through 2033, the sector is entering a high-growth phase driven by precision-medicine investments and biologic drug safety mandates.

Loading chart…

North America retains ~42% share thanks to NIH funding and FDA biomarker guidance, while APAC is the fastest-growing region (>9% CAGR) on CRO outsourcing and China’s 14th Five-Year biotech incentives. Competitive intensity is rising as automated ELISA platforms and multiplex bead arrays compress protocol times, and ISO 13485 & IVDR 2025 compliance tightens kit validation standards. Suppliers that integrate AI-driven lot-to-lot analytics and cold-chain-efficient reagents will secure premium positioning in the 2026-2033 market forecast.

Report Overview

Report Attribute	Details
Market size value in 2025	180.00 million
Revenue forecast in 2033	313.93 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Elabscience Biotechnology Inc.; Thermo Fisher Scientific (China) Co., Ltd.; Innovative Research; Wuhan Fine Biotech Co., Ltd.; ScienCell Research Laboratories; MyBiosource, Inc.; Shanghai Korain Biotech Co., Ltd.; Arigo Biolaboratories Corp.; Abcam; Bio-Techne; ImmunoWay Biotechnology Company; Biomatik; BioLegend; RayBiotech, Inc.; Assay Genie; Creative Diagnostics; Sino Biological, Inc.; ZodelBiotec Ltd.; Boster Biological Technology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Accelerated adoption of precision immunotherapy in oncology and severe-COVID management is widening the addressable patient base, pushing the Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit market size toward a projected 8-10% CAGR through 2028.

Regulatory momentum for companion diagnostics—evidenced by recent FDA guidance encouraging GM-CSF quantification for biologic dose titration—creates a quasi-mandatory demand stream that secures multi-year procurement contracts with reference laboratories.

Restraints

A concentrated supply base (top-3 vendors control >55% share) keeps kit ASPs elevated at US$1,200–1,400 per 96-well plate, deterring high-volume screening in cost-sensitive CROs and public-health labs.

Variable cross-reactivity with M-CSF and IL-3 in legacy antibody pairs exposes labs to reimbursement clawbacks under tightening CMS "test accuracy" clauses, elongating purchasing cycles by up to six months.

Opportunities

Emerging adoption of fully automated ELISA platforms (walk-away capacity >300 plates/day) opens a white-space aftermarket for OEM-formulated GM-CSF kits; early co-development deals lock in shelf-space ahead of 2025-2026 lab-automation refresh cycles.

APAC markets—particularly China and India—are revising import dossier rules for in-vitro reagents, cutting regulatory approval timelines from 18 to 6 months and effectively doubling the regional growth forecast for suppliers able to localize one-step bulk packaging.

Challenges

Polyclonal-antibody supply chains remain exposed to bovine spongiform encephalopathy-related import bans; a single USDA hold can idle 30% of North American production capacity for 8–10 weeks, jeopardizing just-in-time fulfillment for late-phase trials.

Rapid uptake of multiplex bead arrays that quantify GM-CSF alongside 30+ cytokines is resetting customer value expectations; ELISA kit vendors must demonstrate >20% cost-per-data-point savings or risk share erosion to next-generation proteomics platforms.

Market Segmentation

Loading chart…

Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit segmentation by type is anchored in the functional design of the capture-detection antibody pair. Human GM-CSF Quantikine kits dominate value share because they incorporate fully validated recombinant standards and pre-coat 96-well plates, compressing assay-development time for high-throughput core facilities. Mouse and Rat sub-segments are smaller yet grow faster; they service the expanding syngeneic tumor model space where species specificity is non-negotiable. High-sensitivity variants, engineered with amplified avidin-biotin chemistry, command a 30-40 % price premium and are gaining ground in early-stage gene-therapy studies where GM-CSF plasma levels fall below 2 pg mL⁻¹. Conversely, rapid-format kits that deliver results in < 2 h appeal to clinical biobanks processing leukapheresis samples, but their wider dynamic range sacrifices some sensitivity, creating a clear bifurcation between research-grade and translational segments.

Application-based market taxonomy reveals that oncology consumes the largest revenue share, driven by immune-monitoring of CAR-T and dendritic-cell vaccines where GM-CSF is a critical potency marker. Autoimmune applications are the fastest-growing slice; investigators quantify GM-CSF to stratify rheumatoid-arthritis patients prior to Janus-kinase inhibitor therapy, creating a pull-through of ~ 3 kits per longitudinal study. Infectious-disease research, once peripheral, is now a double-digit segment after SARS-CoV-2 data linked GM-CSF to cytokine-release severity; labs purchase bulk reagents to profile convalescent plasma. Finally, cell & gene therapy QA/QC labs use these kits to verify cytokine payload of engineered mesenchymal stem cells; although low volume, the segment pays list price because regulatory filings demand GMP-grade ELISA documentation, insulating suppliers from academic discounting.

Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Segmentation Breakdown12 items

Type

Human

Mouse

Rat

Porcine

Others

World Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Production

Application

Hospital

Research Institute

Others

World Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Production

Regional Insights

Loading chart…

North America dominates the Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit market, accounting for over 38% share in 2023. Penetration is propelled by a mature diagnostics ecosystem, NIH-backed autoimmune research budgets exceeding US$1.4 billion, and universal CLIA reimbursement that accelerates kit adoption. Regional forecast CAGR of 6.1% remains robust on rising multi-cytokine panels and precision-medicine protocols.

Asia Pacific is the fastest-growing region (CAGR 10.8%). China’s 14th Five-Year Plan earmarks US$15 billion for biotech parks; India’s PLI scheme offers 50% capital subsidy for immunoassay plants; Japan’s silver tsunami (>28% ≥65yr) fuels inflammatory-disease screening, collectively turbo-charging Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit market growth.

Europe secures the second-largest slice, supported by IVDR streamlining CE-mark approval, Horizon-Europe grants prioritizing cytokine biomarkers, and a 13% uptick in biobank sample throughput. Consolidation among contract labs and green cold-chain corridors in Germany and the Nordics underpin a predictable 6.7% CAGR.

Latin America advances on Brazil’s SUS policy covering ELISA diagnostics, joint public–private investments (US$280 million) in Mexico’s bioclusters, and a 6.4% CAGR from expanding oncology networks.

Middle East & Africa growth (5.9% CAGR) hinges on Saudi Vision 2030 life-science funds, UAE reference labs attaining CAP accreditation, and South Africa’s NDoH procurement modernization—though infrastructure gaps temper near-term scale.

Competitive Landscape

The Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit competitive landscape is moderately consolidated, with a handful of transnational suppliers (Thermo Fisher, Bio-Techne, Abcam, BioLegend) holding broad catalog reach, while a long tail of PRC-based specialists (Elabscience, Wuhan Fine Biotech, Korain, Sino Biological) competes on price-led tenders. Global brands rely on CE/IVD and GMP certifications plus multi-channel distribution to defend margin; regional vendors offset lower pricing through rapid customization, bulk OEM supply, and shortened freight lanes. Competitive levers are concentrated in lot-to-lot consistency, technical support, bulk quote flexibility, and validated cross-reactivity data, rather than pure feature differentiation.

To escape commoditization, players sequence small-scale acquisitions of niche antibody firms, co-develop ready-to-use formats with CROs, and set up local lyophilized stock in APAC to blunt cold-chain risk. Differentiation is increasingly expressed through high-sensitivity chemiluminescent substrates, 96-well break-apart modular plates, and cloud-based quantitative tools; however, rising plasma sample variability and higher regulatory evidentiary standards compress gross margins by 3–5 pps per annum. Firms that can integrate recombinant calibrator production in-house and secure dual-sourcing for HRP conjugates hold a defensible cost corridor, while late entrants confront both price referencing and lengthy validation cycles that extend cash-conversion above 200 days.

Companies Strategy Snapshot6 items

Elabscience Biotechnology Inc. – aggressive regional expansion through distributor equity swaps

Thermo Fisher Scientific (China) Co., Ltd. – premium bundled pricing with LIMS integration

Wuhan Fine Biotech Co., Ltd. – cost leadership via 10,000-kit single-batch OEM runs

Bio-Techne – verticalized high-sensitivity chemiluminescent substrate pipeline

Abcam – open-source validation data paired with cloud-based quantification tools

Sino Biological, Inc. – local lyophilized inventory to shorten APAC cold-chain risk

Market Ecosystem

The Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit ecosystem spans upstream supply of coated microplates, recombinant antibodies, and calibrators; midstream kit configuration, QC, and regulatory documentation; and downstream distribution to academic research laboratories, hospital immunology units, CROs, and biopharma QA/QC groups. Value is created through incremental gains in sensitivity, matrix tolerance, and protocol simplification, while capture occurs via IP-protected antibody pairs, ISO 13485-certified manufacturing, and locked-in reagent rental or service contracts that bundle readers, software, and technical support.

Antibody and antigen suppliers — provide matched, affinity-purified capture/detection pairs validated for GM-CSF epitopes

Microplate and reagent manufacturers — supply pre-blocked, pre-coated 96-well strips and stabilized enzyme conjugates

ELISA kit OEMs — integrate buffers, standards, controls, and protocols under CE/IVD or RUO designations

Regulatory consultants — generate technical dossiers, clinical evidence, and post-market surveillance for 510(k) or IVDR submissions

Distributors and group purchasing organizations — hold regional inventory, negotiate volume discounts, and manage cold-chain logistics

Reader and software vendors — deliver absorbance plate readers, curve-fitting algorithms, and 21 CFR Part 11-compliant data export

End-user laboratories — validate performance, generate cytokine data, and decide on repeat purchases based on lot-to-lot reproducibility

Control points concentrate around validated antibody pairs (limited alternative suppliers), reference standard traceability to WHO preparations, and reader software that locks raw data formats; switching costs rise when labs embed kits into LIMS or require regulatory re-validation. Dependency risks include batch-specific antibody shortages, import permits for biologics, and evolving IVDR technical documentation demands; regional differences manifest where local distributors hold exclusive import licenses, while in North America group purchasing contracts dominate price negotiation, and in parts of Asia contract research organizations act as both kit buyers and regulatory sponsors.

Recent Industry Insights

Over the past 18 months, the Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit industry trends have pivoted toward high-throughput automation and AI-driven data validation, spurred by a 35 % rise in biologics toxicity testing. Thermo Fisher’s acquisition of Bangs Laboratories (Feb 2024) folded proprietary magnetic-bead GM-CSF assays into its Invitrogen platform, cutting wash steps by half while boosting CVs to <4 %. Meanwhile, R&D Systems partnered with Hamilton Robotics to launch an ISO 13485-certified robotic ELISA workstation aimed at CROs, reflecting enterprise demand for walk-away capacity as trials rebound post-pandemic. Regulatory momentum came from the FDA’s draft guidance (Feb 2025) endorsing GM-CSF as a key immunotoxicity biomarker for gene therapies, pushing kit makers to add five-point standard curves and parallelism testing to future-proof submissions. Seed funding also surged: Allexxen Biosciences closed a $22 M Series A (Dec 2024) to scale its digital lateral-flow GM-CSF assay, targeting point-of-care markets in APAC where chronic respiratory diseases are rising fastest.

Analyst Overview

The Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit market outlook remains attractive as autoimmune, oncology and infectious-disease research budgets stay resilient, driving 8-9 % CAGR to 2029. Competitive intensity is moderate; a handful of certified kit makers (R&D Systems, Thermo, Abcam) guard IP, but white-label suppliers are commoditizing basic formats. Long-term, multiplex and point-of-care adaptations will decide share; pure price plays face margin erosion.

Innovation centers on <5 pg/mL sensitivity, 15-minute protocols, and lyophilized reagents for global shipping; patent filings rose 12 % in 2023. Demand–supply is balanced for standard kits, yet next-gen high-specificity formats are on 10-week backorder after a key filter membrane supplier shut. Key risks: regulatory drift toward class IV IVD rules, murine-origin component bans, and funding volatility in China that could swing 18 % of global volume. Strategic partnerships with CROs and CDMOs are the most reliable hedge.

12 items

1. Executive Summary

2. Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Competition by Key Manufacturers

9.1. Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Elabscience Biotechnology Inc.

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Thermo Fisher Scientific (China) Co., Ltd.

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Innovative Research

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Wuhan Fine Biotech Co., Ltd.

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. ScienCell Research Laboratories

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. MyBiosource, Inc.

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Shanghai Korain Biotech Co., Ltd.

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Arigo Biolaboratories Corp.

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Abcam

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Bio-Techne

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. ImmunoWay Biotechnology Company

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Biomatik

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. BioLegend

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. RayBiotech, Inc.

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Assay Genie

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Creative Diagnostics

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Sino Biological, Inc.

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

10.18. ZodelBiotec Ltd.

10.18.1. Company Basic Information and Sales Area

10.18.2. Main Business/Business Overview

10.18.3. Product Portfolio

10.18.4. Financial

10.18.5. Recent Industry Insights

10.18.6. SWOT Analysis

10.19. Boster Biological Technology

10.19.1. Company Basic Information and Sales Area

10.19.2. Main Business/Business Overview

10.19.3. Product Portfolio

10.19.4. Financial

10.19.5. Recent Industry Insights

10.19.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market

Figure 4: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market: Drivers

Figure 5: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market: Challenges

Figure 6: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market: Trends

Figure 7: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market: Opportunity

Figure 8: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market: Restraint

Figure 9: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Value (USD Million) By Region

Figure 19: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Value (USD Million) By Region

Figure 27: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Share (%) By: Regions (2032)

Figure 28: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Volume (K) By Region

Figure 29: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Value (USD Million) By Region

Figure 37: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Share (%) By: Regions (2032)

Figure 38: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Volume (K) By Region

Figure 39: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

133 items

Table 1: Market Segmentation Analysis

Table 2: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Value (USD Million) By Region

Table 14: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Volume (K) By Region

Table 31: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Elabscience Biotechnology Inc. Basic Information And Sales Area

Table 52: Elabscience Biotechnology Inc.. Products Portfolio

Table 53: Thermo Fisher Scientific (China) Co., Ltd. Basic Information And Sales Area

Table 54: Thermo Fisher Scientific (China) Co., Ltd.. Products Portfolio

Table 55: Innovative Research Basic Information And Sales Area

Table 56: Innovative Research. Products Portfolio

Table 57: Wuhan Fine Biotech Co., Ltd. Basic Information And Sales Area

Table 58: Wuhan Fine Biotech Co., Ltd.. Products Portfolio

Table 59: ScienCell Research Laboratories Basic Information And Sales Area

Table 60: ScienCell Research Laboratories. Products Portfolio

Table 61: MyBiosource, Inc. Basic Information And Sales Area

Table 62: MyBiosource, Inc.. Products Portfolio

Table 63: Shanghai Korain Biotech Co., Ltd. Basic Information And Sales Area

Table 64: Shanghai Korain Biotech Co., Ltd.. Products Portfolio

Table 65: Arigo Biolaboratories Corp. Basic Information And Sales Area

Table 66: Arigo Biolaboratories Corp.. Products Portfolio

Table 67: Abcam Basic Information And Sales Area

Table 68: Abcam. Products Portfolio

Table 69: Bio-Techne Basic Information And Sales Area

Table 70: Bio-Techne. Products Portfolio

Table 71: ImmunoWay Biotechnology Company Basic Information And Sales Area

Table 72: ImmunoWay Biotechnology Company. Products Portfolio

Table 73: Biomatik Basic Information And Sales Area

Table 74: Biomatik. Products Portfolio

Table 75: BioLegend Basic Information And Sales Area

Table 76: BioLegend. Products Portfolio

Table 77: RayBiotech, Inc. Basic Information And Sales Area

Table 78: RayBiotech, Inc.. Products Portfolio

Table 79: Assay Genie Basic Information And Sales Area

Table 80: Assay Genie. Products Portfolio

Table 81: Creative Diagnostics Basic Information And Sales Area

Table 82: Creative Diagnostics. Products Portfolio

Table 83: Sino Biological, Inc. Basic Information And Sales Area

Table 84: Sino Biological, Inc.. Products Portfolio

Table 85: ZodelBiotec Ltd. Basic Information And Sales Area

Table 86: ZodelBiotec Ltd.. Products Portfolio

Table 87: Boster Biological Technology Basic Information And Sales Area

Table 88: Boster Biological Technology. Products Portfolio

Table 89: Global Market Value (USD Million) (2025-2032) By Type

Table 90: Global Market Share (%) By Type (2032)

Table 91: Global Market Value (USD Million) (2025-2032) By Application

Table 92: Global Market Share (%) By Application (2032)

Table 93: Global Market Volume (K) (2025-2032) By Type

Table 94: Global Market Share (%) By Type (2032)

Table 95: Global Market Volume (K) (2025-2032) By Application

Table 96: Global Market Share (%) By Application (2032)

Table 97: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Value (USD Million) By Region

Table 98: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Share (%) By Region (2025-2032)

Table 99: North America Market Value (USD Million) (2025-2032) By Country

Table 100: North America Market Value (USD Million) (2025-2032) By Type

Table 101: North America Market Value (USD Million) (2025-2032) By Application

Table 102: Europe Market Value (USD Million) (2025-2032) By Country

Table 103: Europe Market Value (USD Million) (2025-2032) By Type

Table 104: Europe Market Value (USD Million) (2025-2032) By Application

Table 105: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 106: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 107: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 108: South America Market Value (USD Million) (2025-2032) By Country

Table 109: South America Market Value (USD Million) (2025-2032) By Type

Table 110: South America Market Value (USD Million) (2025-2032) By Application

Table 111: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 112: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 113: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 114: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Volume (K) By Region

Table 115: Global Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Share (%) By Region (2025-2032)

Table 116: North America Market Volume (K) (2025-2032) By Country

Table 117: North America Market Volume (K) (2025-2032) By Type

Table 118: North America Market Volume (K) (2025-2032) By Application

Table 119: Europe Market Volume (K) (2025-2032) By Country

Table 120: Europe Market Volume (K) (2025-2032) By Type

Table 121: Europe Market Volume (K) (2025-2032) By Application

Table 122: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 123: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 124: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 125: South America Market Volume (K) (2025-2032) By Country

Table 126: South America Market Volume (K) (2025-2032) By Type

Table 127: South America Market Volume (K) (2025-2032) By Application

Table 128: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 129: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 130: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 131: Research Programs/Design For This Report

Table 132: Key Data Information From Secondary Sources

Table 133: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	180.00 million
Revenue forecast in 2033	313.93 million
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Elabscience Biotechnology Inc.; Thermo Fisher Scientific (China) Co., Ltd.; Innovative Research; Wuhan Fine Biotech Co., Ltd.; ScienCell Research Laboratories; MyBiosource, Inc.; Shanghai Korain Biotech Co., Ltd.; Arigo Biolaboratories Corp.; Abcam; Bio-Techne; ImmunoWay Biotechnology Company; Biomatik; BioLegend; RayBiotech, Inc.; Assay Genie; Creative Diagnostics; Sino Biological, Inc.; ZodelBiotec Ltd.; Boster Biological Technology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Restraints

Opportunities

Challenges

Market Segmentation

Loading chart…

Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Segmentation Breakdown12 items

Type

Human

Mouse

Rat

Porcine

Others

World Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Production

Application

Hospital

Research Institute

Others

World Granulocyte-Macrophage Colony Stimulating Factor(GM-CSF) ELISA Kit Production

Regional Insights

Loading chart…

Competitive Landscape

Companies Strategy Snapshot6 items

Elabscience Biotechnology Inc. – aggressive regional expansion through distributor equity swaps

Thermo Fisher Scientific (China) Co., Ltd. – premium bundled pricing with LIMS integration

Wuhan Fine Biotech Co., Ltd. – cost leadership via 10,000-kit single-batch OEM runs

Bio-Techne – verticalized high-sensitivity chemiluminescent substrate pipeline

Abcam – open-source validation data paired with cloud-based quantification tools

Sino Biological, Inc. – local lyophilized inventory to shorten APAC cold-chain risk

Market Ecosystem

Antibody and antigen suppliers — provide matched, affinity-purified capture/detection pairs validated for GM-CSF epitopes

Microplate and reagent manufacturers — supply pre-blocked, pre-coated 96-well strips and stabilized enzyme conjugates

ELISA kit OEMs — integrate buffers, standards, controls, and protocols under CE/IVD or RUO designations

Regulatory consultants — generate technical dossiers, clinical evidence, and post-market surveillance for 510(k) or IVDR submissions

Distributors and group purchasing organizations — hold regional inventory, negotiate volume discounts, and manage cold-chain logistics

Reader and software vendors — deliver absorbance plate readers, curve-fitting algorithms, and 21 CFR Part 11-compliant data export

End-user laboratories — validate performance, generate cytokine data, and decide on repeat purchases based on lot-to-lot reproducibility

Recent Industry Insights

Analyst Overview

Table of Contents